Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An autosomal dominant hypocalcemia disease that has material basis in heterozygous mutation in the GNA11 gene on chromosome 19p13.
Features include always present findings: Hypocalcemia; and common findings: Paresthesia and Muscle spasm. 6 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 1 | Paresthesia |
Muscles |
GNA11 encodes G protein subunit alpha 11 (359 aa). Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades. Highest expression in Brain Cerebellum (153.0 TPM) and Brain Cerebellar Hemisphere (140.5 TPM).
Autosomal dominant hypocalcemia 2 is associated with mutations in the GNA11 gene on chromosome 19.
The GNA11 protein participates in G alpha (q):RGS dissociates to inactive G alpha (q) pathway.
GNA11 is classified as a druggable target (Clinically Actionable category) with score 5.2.
Isolated and classic cutis marmorata telangiectatica congenita (CMTC) are considered capillary malformations by the International Society for the Study of Vascular Anomalies. Clinically, CMTC is diagnosed by characteristic congenital erythematous-to-violaceous net-like or marbled areas of skin. Several groups have attempted to develop clinical diagnostic criteria , although no consensus clinical diagnostic criteria for isolated and classic CMTC have been universally accepted . For a proposed classification system for the physical findings of CMTC, see .
Isolated and classic CMTC should be suspected in individuals with the following clinical and family history findings.
No approved treatments are currently available for autosomal dominant hypocalcemia 2. The disease remains an area of unmet medical need.
No clinical practice guidelines for cutis marmorata telangiectatica congenita (CMTC) have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with isolated and classic CMTC, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with Isolated and Classic Cutis Marmorata Telangiectatica Congenita
Table 6. Recommended Surveillance for Individuals with Isolated and Classic Cutis Marmorata Telangiectatica Congenita
System/Concern |
|---|
1 clinical trial registered. Interventions under study include other interventions. Research is primarily industry-sponsored.
29 publications have been identified in PubMed for autosomal dominant hypocalcemia 2. Research spans Case Report / Case Series (31%), Basic Science / Preclinical (31%), and Review / Meta-Analysis (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 9 | 31% |
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 2:56 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
1
Muscle spasm |
Growth and development | 1 | Postnatal growth retardation |
To date, nearly 500 individuals with all clinical subtypes of cutis marmorata telangiectatica congenita (CMTC), including isolated and classic CMTC, have been published (reviewed in ). CMTC should be distinguished from cutis marmorata (CM), which is a normal physiologic finding that is apparent at rest in some newborns because of immaturity of the vascular system. CM consists of a homogeneous, fine, lacy, or reticular capillary change that worsens (or becomes apparent) with cold or emotion, completely (or nearly completely) resolves with warming, and usually fades by age four to six months. No ulcerations or skin atrophy are present.
Source: GeneReviews — "Isolated and Classic Cutis Marmorata Telangiectatica Congenita"
No clinically relevant genotype-phenotype correlations for isolated and classic CMTC have been identified.
Source: GeneReviews — "Isolated and Classic Cutis Marmorata Telangiectatica Congenita"
Clinical findings
Source: GeneReviews — "Isolated and Classic Cutis Marmorata Telangiectatica Congenita"
Isolated and classic cutis marmorata telangiectatica congenita (CMTC) are congenital conditions; similar skin lesions occurring later in life are referred to as livedo reticularis or livedo racemosa (see A CMTC-like skin appearance seen later in life at the end of this section). The primary differential diagnosis for congenital isolated CMTC is physiologic cutis marmorata (CM). CM is a normal physiologic finding that is apparent at rest in a minority of newborns. CM consists of a homogeneous, fine, lacy, or reticular capillary change that worsens (or becomes apparent) with cold or emotion, completely (or nearly completely) resolves with warming, and usually fades by age four to six months. No ulcerations or skin atrophy are present. In contrast, while CMTC lesions often show changes with warming or strong emotion, the lesions do not rapidly resolve, regardless of the intervention. If complete or near-complete resolution occurs acutely with any intervention, the individual has physiologic CM, not CMTC. Syndromic CMTC refers to CMTC or CMTC-like lesions associated with a known syndrome . Some of these diagnoses have early-onset clinical and laboratory findings that rule out isolated and classic CMTC. For others, adhering to the diagnostic criteria proposed by minus the "absence of venectasia" criterion or using the diagnostic criteria described in should lead to correct identification of isolated or classic CMTC. Table 3. Syndromes of Known Genetic Cause in Which CMTC or CMTC-Like Lesions Are Present
Involved Genes /Chromosomes | Syndrome | Genetic Mechanism (MOI) | Key Features / Comment |
|---|---|---|---|
RBPJ | Adams-Oliver syndrome (OMIM PS100300) | Germline pathogenic variant(s) (AD, AR) | Should be suspected in any persons w/CMTC in combination w/aplasia cutis congenita of scalp, terminal transverse limb reduction defects, complex congenital heart disease, or dilated, tortuous vein(s) on scalp BRD4 HDAC8 NIPBL RAD21 SMC1A SMC3 |
Cornelia de Lange syndrome | Germline pathogenic variant (AD, XL)1 | Cutis marmorata that is much more prominent than expected is persistent (60% of affected persons); also assoc w/synophrys, growth failure, feeding difficulties, limb deformity, ID CBS | — |
MTHFR | Homocystinuria (See Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency Homocystinuria due to MTHFR Deficiency.) | Germline pathogenic variants (AR) | Cutis marmorata that is much more prominent than expected persistent; also assoc w/tall stature, ectopia lentis, DD |
RASA1 | RASA1-related Parkes Weber syndrome (See Capillary Malformation-Arteriovenous Malformation Syndrome.) | Germline pathogenic variant (AD) | Capillary malformations (sometimes reticulate or lace-like) ± overgrowth |
POLE | IMAGE-I syndrome (OMIM 618336)/ FILS syndrome (OMIM 615139) | Germline pathogenic variants (AR) | CMTC-like lesions (often present at birth), IUGR, s... |
Source: GeneReviews — "Isolated and Classic Cutis Marmorata Telangiectatica Congenita"
Genetic testing for GNA11 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for autosomal dominant hypocalcemia 2 has been reported in the published literature.
System/Concern | Evaluation | Comment |
|---|---|---|
Skin | Full skin exam to identify areas of skin atrophy ulceration | Consider referral to dermatologist. Musculoskeletal/ |
Pain | Assessment for significant limb asymmetry, abnormal joints, or weakness in affected limbs | Consider referral to orthopedist if gait is affected or leg length discrepancy is 1.5 cm. Assessment for chronic pain temperature dysregulation |
Eyes | Dilated eye exam w/intraocular pressure measurement peripheral vascular imaging (as soon as feasible) | To screen for glaucoma peripheral retinal vascular abnormalities Genetic |
counseling | By genetics professionals1 | To obtain a pedigree inform affected persons their families re nature, MOI (not typically inherited), implications of CMTC to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with Isolated and Classic Cutis Marmorata Telangiectatica Congenita Manifestation/Concern | Treatment | Considerations/Other |
Skin ulceration | Ulcer care may need to be less aggressive than other wound treatments. | Since skin w/reticulate erythema does not heal like uninvolved skin, standard ulcer care is not typically sufficient. Ongoing cleaning of ulcer bed is needed. |
vascular lesions | Frequency-doubled Nd:YAG, Q-switched alexandrite, pulsed dye laser therapy may be tried but has mixed results depending on severity depth of lesions.2 | Anecdotally, some children worsen w/this therapy.; Laser therapy is typically not needed; usually done for cosmetic reasons. Chronic pain / Temperature |
dysregulation | Lumbar sympathetic blockade may be considered. | Used successfully to treat chronic pain marked temperature difference in an affected foot in 1 child w/classic CMTC3 Leg length |
discrepancy | Mild leg length discrepancy: shoe lifts or orthotics may be considered. | Severe leg length discrepancy: epiphysiodesis or limb lengthening surgery may be considered. |
hypoplastic limb | Physical therapy | Glaucoma peripheral retinal vascular |
abnormalities | Standard treatment per ophthalmologist | Issues related to physical appearance |
Source: GeneReviews — "Isolated and Classic Cutis Marmorata Telangiectatica Congenita"
Avoid blood draws or IV placement in affected limbs because of potential vein fragility. Cold exposure of affected limbs may be painful for some people with CMTC.
Source: GeneReviews — "Isolated and Classic Cutis Marmorata Telangiectatica Congenita"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Isolated and Classic Cutis Marmorata Telangiectatica Congenita"
1 trial found
Evaluation
Frequency |
|---|
Skin | Close monitoring for early signs of impending ulceration of skin | As determined at initial eval |
Musculoskeletal | Monitoring of limb length girth | Annually until skeletal maturity Assessment for pain, weakness, temperature dysregulation |
Eyes | Ophthalmologic eval to incl measurement of intraocular pressure consideration of peripheral retinal vascular imaging | Every 6 mos until age 4 yrs, then annually (throughout lifetime)1 or when there is ocular pain or visible corneal clouding |
Self-esteem | Monitoring of coping skills related to visible differences | Annually starting at school age 1. |
Source: GeneReviews — "Isolated and Classic Cutis Marmorata Telangiectatica Congenita"
Phenotype severity distribution: 1 always present feature, 2 common features.
Laboratory research |
9 |
31% |
Research summaries | 4 | 14% |
Disease patterns and progression | 4 | 14% |
New treatment approaches | 2 | 7% |
Testing and diagnosis research | 1 | 3% |
Yang Y (2026). [PMID: 42101462](https://pubmed.ncbi.nlm.nih.gov/42101462/). *Endocr Connect*. [Epidemiology / Natural History]
Sonmez Ince M (2026). [PMID: 41757505](https://pubmed.ncbi.nlm.nih.gov/41757505/). *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. [Case Report / Case Series]
Zhao N (2026). [PMID: 41898235](https://pubmed.ncbi.nlm.nih.gov/41898235/). *Biomedicines*. [Basic Science / Preclinical]
Çordan İ (2026). [PMID: 42017099](https://pubmed.ncbi.nlm.nih.gov/42017099/). *Cureus*. [Case Report / Case Series]
Bibik E (2026). [PMID: 41952051](https://pubmed.ncbi.nlm.nih.gov/41952051/). *Clin Endocrinol (Oxf)*. [Case Report / Case Series]
Dzhamaludinova AA (2026). [PMID: 42227095](https://pubmed.ncbi.nlm.nih.gov/42227095/). *Probl Endokrinol (Mosk)*. [Epidemiology / Natural History]
Boisen IM (2025). [PMID: 38920275](https://pubmed.ncbi.nlm.nih.gov/38920275/). *The Journal of clinical endocrinology and metabolism*. [Basic Science / Preclinical]
Benson MR (2025). [PMID: 39658204](https://pubmed.ncbi.nlm.nih.gov/39658204/). *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. [Basic Science / Preclinical]
Hannan FM (2025). [PMID: 40086735](https://pubmed.ncbi.nlm.nih.gov/40086735/). *The Journal of biological chemistry*. [Review / Meta-Analysis]
Gaadi A (2025). [PMID: 40096731](https://pubmed.ncbi.nlm.nih.gov/40096731/). *La Tunisie medicale*. [Epidemiology / Natural History]